Clinical Trial Search

Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04

Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9

Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg

Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) — 514.6; 512.0 dyn*sec/cm^5 — p=0.0220

Primary: Volume of Distribution of Radiolabeled GSK2256098 Measured by PET Scan — 1.0811; 1.3027; 0.8117; 0.5571 Milliliter per cubic centimeter(mL/cm^3)

Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 8; 8; 2 participants

Primary: Change in Six-minute Walk Distance — 1.53; 9.45 meters

Primary: Plasma Estradiol (E2) Level — -40; -4 % change from baseline

Primary: Peak Plasma Concentration of 14C-BaP Cmax — 7.07; 1.60 fg [14C]-BaP/mL plasma

Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883

Primary: Change From Baseline in Patient Global Impression of Severity (PGI-S) Score in Cohort A Participants at Approximately 30 Minutes of Previous Dose of Inhaled Treprostinil…

Primary: Changes From Baseline in Peak Exercise Mean Pulmonary Artery Pressure (mPAP), Transpulmonary Pressure Gradient (TPG), and Pulmonary Capillary Wedge Pressure (PCWP)…

Primary: Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks — 1.28 mL/min/kg

Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm

Primary: Change From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24 — 417.2 dynes*sec/cm^5

Primary: Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Body…

Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2

Primary: Change From Baseline in Pulmonary Vascular Resistance — -52.2 dynes.sec/cm5

Primary: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks — -27.6; -168.4; -258.9; 802.0 dynes*sec/cm^5 — p=0.0030

Primary: Change in Mean Pulmonary Artery Pressure (MPAP) — 6.5; 4.3 mmHg

Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg

Primary: Time to First Clinical Worsening Event — 60.58; 49.31 weeks — p=0.0275

Primary: Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR) — 21.2; -74.9 dyne•s/cm^5 — p=0.0310

Primary: Mean Pulmonary Arterial Pressure Change From Baseline — -1.0; -0.73 mmHg

Primary: Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters — 16; 24 participants

Primary: Pulmonary Vascular Resistance (PVR) — 6.7 woods unit

Primary: Number of Participants Reporting at Least One Adverse Event — 41; 55; 73; 13 Participants

Primary: Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12 — 53.59 Meters — p=<0.001

Primary: Change From Baseline in Six Minute Walk Distance (Meters) — 414.5; 461.7; 448.9; 483.0 meters

Primary: Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks — 382.94; 351.18 meters